Research Article
Virological Breakthrough: A Risk Factor for Loss to Followup in a Large Community-Based Cohort on Antiretroviral Therapy
| | All naΓ―ve adults with initial viral suppression: | NaΓ―ve adults with initial virological breakthrough: | | Remain suppressed | Initial viral breakthrough | | Resuppressed | Failed | |
| Total number | 2109 | 850 | β | 567 (67%) | 283 (33%) | β | Female gender: (%) | 1415 (67) | 585 (68) |
*
| 386 (68) | 200 (71) |
*
| Age at treatment start: mean years (Β±SD) | 35 (Β±8.7) | 33 (Β±8.0) |
**
| 34 (Β±8.3) | 32 (Β±7.5) |
**
| WHO stage 1 or 2: (%) | 611 (29) | 228 (27) |
*
| 159 (28) | 67 (24) |
*
| WHO stage 3 or 4: (%) | 1495 (71) | 622 (73) |
*
| 406 (72) | 216 (76) |
*
| WHO stage unknown | 3 | 0 | β | 0 | 0 | β | Baseline CD4: median cells/mm3 (IQR) | 117 (62β168) | 110 (50β163) | # | 110 (57β171) | 83 (34β138) | # | Baseline viral load: median copies/mL (IQR) | 4.82 (4.39β5.26) | 4.94 (4.51β5.30) | # | 4.86 (4.48β5.24) | 5.07 (4.70β5.48) | # |
|
|
*Chi-squared.
**
-test. #Mann-Whitney test.
|